NCT06895512View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

386

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG

HLX15-IV

recombinant anti-CD38 human monoclonal antibody injection

DRUG

Darzalex

recombinant anti-CD38 human monoclonal antibody injection

Trial Locations (1)

Unknown

Zhongshan hospital, Shanghai, Shanghai

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT06895512 - A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter